When EMA and FDA decisions conflict: differences in patients or in regulation?

@article{Wolfe2013WhenEA,
  title={When EMA and FDA decisions conflict: differences in patients or in regulation?},
  author={Sidney M. Wolfe},
  journal={BMJ : British Medical Journal},
  year={2013},
  volume={347}
}
  • Sidney M. Wolfe
  • Published 2013
  • Medicine
  • BMJ : British Medical Journal
    • In his new regular column Sid Wolfe asks why the two regulatory bodies have arrived at different decisions on the same diet drugs 
    View on BMJ
    klinikfarmakoloji.com
    Top 3 of 13 Citations
    Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
    Saad Alqahtani, Enrique Seoane-Vazquez, … Tewodros EgualePharmacoepidemiology and drug safety2015
    Illicit Internet availability of drugs subject to recall and patient safety consequences
    Tim Ken Mackey, Phyo Wai Aung, Bryan A. LiangInternational Journal of Clinical Pharmacy2015
    Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles.
    Andrew J. Krentz, K Fujioka, Marcus HompeschDiabetes, obesity & metabolism2016

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 13 CITATIONS

    Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?

    Illicit Internet availability of drugs subject to recall and patient safety consequences

    Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles.

    VIEW 1 EXCERPT
    CITES BACKGROUND

    Horizons in the Pharmacotherapy of Obesity

    Safety and tolerability profile of new antiepileptic drug treatment in children with epilepsy

    Current Perspectives on Long-term Obesity Pharmacotherapy.

    Pharmacotherapy for weight loss

    Comparing the effects of short-term fasting therapy and low-calorie diet on anthropometric and leptin measures among obese or overweight persons: Randomized controlled trial

    Xiexin Tang ameliorates dyslipidemia in high-fat diet-induced obese rats via elevating gut microbiota-derived short chain fatty acids production and adjusting energy metabolism.

    Capsaicinoids : a potential role for weight management

    VIEW 1 EXCERPT
    CITES BACKGROUND

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 12 REFERENCES

    Withdrawal of sibutramine in Europe

    European regulatory body recommends suspension of rosiglitazone

    Elevated heart rate: a "new" cardiovascular risk factor?

    22529: lorcaserin hydrochloride tablets, 10 mg [FDA briefing document for 10 May 2012 advisory committee meeting

    • Fda, Nda

    Advisory Committee meeting for phentermine/topiramate (Qnexa) [briefing memo

    • E Colman

    Application number 022529Orig1s000: approval letter

    Clinical briefing document: Endocrinologic and Metabolic Drugs Advisory Committee meeting

    FDA approves Belviq to treat some overweight or obese adults.

    • Medicine
    • Home healthcare nurse
    • 2012

    FDA approves weight-management drug Qsymia

    Medications target long-term weight control